Rizwan Romee, MD
Associate Professor of Medicine, Harvard Medical School, Dana Farber Cancer Institute
Dr. Rizwan Romee, MD, is an Associate Professor of Medicine at Harvard Medical School and Director of the Haploidentical Donor Transplant Program at Dana Farber Cancer Institute (DFCI), Boston, USA. He is also the Principal Investigator of the Romee Lab for NK Cell Gene Manipulation and Therapy at DFCI. The research focus of his laboratory is genetic manipulation of the human NK cells to enhance their anti-tumor function and simultaneously modulate the highly immune suppressive tumor microenvironment (TME). His work at Washington University helped describe human memory-like NK cells with enhanced anti-tumor activity and he led a first in-human clinical trial of these cells in patients with relapsed and refractory AML demonstrating safety and promising activity. He is currently leading the translational NK cell program at DFCI evaluating memory-like NK cells in combination with novel immune-modulatory agents in patients with advanced malignancies including AML and MDS relapsed after stem cell transplantation, MRD+ multiple myeloma (in combination with CD38 ARM) and head and neck cancer (in combination with CTLA-4 blockade/ipilimumab and IL-15 super-agonist).